Tandem Freedom - Feasibility Trial 1

Inclusion Criteria:

• Age ≥18 years old

• Diagnosis of type 1 diabetes for at least 1 year

• Current Control-IQ user, having been prescribed Control-IQ for at least 3 months

• HbA1c ≤10%, recorded in the last 3 months

• Investigator has confidence that the participant can successfully operate all studydevices and is capable of adhering to the protocol, including performing the weekendhotel observed setting portion of the study.

• Willing to use only aspart (novorapid) or lispro (humalog) insulin with the studypump, with no use of long-acting basal insulin injections, or inhaled insulin withthe study pump.

• Have current glucagon product to treat severe hypoglycemia (injectable or nasal) athome (site will provide prescription if they do not have one)

Exclusion Criteria:

• More than 1 episode of diabetic ketoacidosis (DKA) in the past 6 months

• More than 1 episode of severe hypoglycemia (needing assistance) in the past 6 months

• Inpatient psychiatric treatment in the past 6 months

• For Female: Currently pregnant or planning to become pregnant during the time periodof study participation

1. A negative pregnancy test will be required for all females of child-bearingpotential

2. Counseling on appropriate birth control options will be provided to all femalesof child-bearing potential

• Concurrent use of any non-insulin glucose-lowering agent, other than metformin (forexample, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors,sulfonylureas).

• Hemophilia or any other bleeding disorder

• Hemoglobinopathy

• History of heart, liver, lung or kidney disease determined by investigator tointerfere with the study

• History of allergic reaction to Humalog or Novorapid

• Use of any medications determined by investigator to interfere with study

• Significant chronic kidney disease (which could impact CGM accuracy ininvestigator's judgment) or hemodialysis

• Concurrent use of any medication that could interfere with the study CGM, such ashydroxyurea

• History of adrenal insufficiency

• History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that isnot appropriately treated

• History of gastroparesis

• A condition, which in the opinion of the investigator or designee, would put theparticipant or study at risk

• Participation in another pharmaceutical or device trial at the time of enrollment oranticipated for during the time period of study participation

• Employed by, or having immediate family members employed by Tandem Diabetes Care,Inc., or having a direct supervisor at place of employment who is also directlyinvolved in conducting the clinical trial (as a study investigator, coordinator,etc.); or having a first-degree relative who is directly involved in conducting theclinical trial